BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Quinn J, Musa A, Kantor A, McClements ME, Cehajic-Kapetanovic J, MacLaren RE, Xue K. Genome-Editing Strategies for Treating Human Retinal Degenerations. Hum Gene Ther 2021;32:247-59. [PMID: 32993386 DOI: 10.1089/hum.2020.231] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Nambiar TS, Baudrier L, Billon P, Ciccia A. CRISPR-based genome editing through the lens of DNA repair. Molecular Cell 2022;82:348-88. [DOI: 10.1016/j.molcel.2021.12.026] [Reference Citation Analysis]
2 Cehajic-kapetanovic J, Singh MS, Zrenner E, Maclaren RE. Bioengineering strategies for restoring vision. Nat Biomed Eng. [DOI: 10.1038/s41551-021-00836-4] [Reference Citation Analysis]
3 Fry LE, McClements ME, MacLaren RE. Analysis of Pathogenic Variants Correctable With CRISPR Base Editing Among Patients With Recessive Inherited Retinal Degeneration. JAMA Ophthalmol 2021;139:319-28. [PMID: 33507217 DOI: 10.1001/jamaophthalmol.2020.6418] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Rasoulinejad SA, Maroufi F. CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases. Mol Biotechnol 2021;63:768-79. [PMID: 34057656 DOI: 10.1007/s12033-021-00345-4] [Reference Citation Analysis]
5 Wen J, Cao T, Wu J, Chen Y, Zhi S, Huang Y, Zhen P, Wu G, Aagaard L, Zhong J, Liang P, Huang J. Single AAV-mediated CRISPR-Nme2Cas9 efficiently reduces mutant hTTR expression in a transgenic mouse model of transthyretin amyloidosis. Mol Ther 2021:S1525-0016(21)00262-8. [PMID: 33992807 DOI: 10.1016/j.ymthe.2021.05.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Maynard LH, Humbert O, Peterson CW, Kiem HP. Genome editing in large animal models. Mol Ther 2021;29:3140-52. [PMID: 34601132 DOI: 10.1016/j.ymthe.2021.09.026] [Reference Citation Analysis]
7 Priglinger C, Fischer MD. [From Bench to Bedside: Challenges in the Development of Genetherapeutic Approaches]. Klin Monbl Augenheilkd 2022;239:261-2. [PMID: 35316852 DOI: 10.1055/a-1739-3825] [Reference Citation Analysis]
8 Daich Varela M, Cabral de Guimaraes TA, Georgiou M, Michaelides M. Leber congenital amaurosis/early-onset severe retinal dystrophy: current management and clinical trials. Br J Ophthalmol. [DOI: 10.1136/bjophthalmol-2020-318483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Piotter E, McClements ME, MacLaren RE. Therapy Approaches for Stargardt Disease. Biomolecules 2021;11:1179. [PMID: 34439845 DOI: 10.3390/biom11081179] [Reference Citation Analysis]
10 Flotte TR. CRISPR Keeps Things Fresh: Next-Generation Tools for Gene Editing. Hum Gene Ther 2021;32:235-6. [PMID: 33750218 DOI: 10.1089/hum.2021.29152.trf] [Cited by in F6Publishing: 1] [Reference Citation Analysis]